---
schema_version: "secwatch.filing_event.v1"
accession: "0000875320-21-000031"
form_type: "8-K"
ticker: "VRTX"
cik: "0000875320"
company_name: "VERTEX PHARMACEUTICALS INC / MA"
filed_at: "2021-11-02T23:59:59+00:00"
generated_at: "2026-06-28T15:28:33.349158+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.85
calibrated_materiality_score: 0.85
confidence: "high"
source: SEC EDGAR
---

# Vertex Q3 revenue $1.98B (+29% YoY); raises FY2021 guidance to $7.4-7.5B

## Summary
- Product revenues of $1.984B (+29% YoY); GAAP diluted EPS $3.28, Non-GAAP $3.56.
- Raised FY2021 product revenue guidance to $7.4-7.5B from prior $7.2-7.4B.
- TRIKAFTA/KAFTRIO net revenues $1.556B, up 62% YoY from $960M.
- Pipeline: VX-880 T1D positive data (1st patient); VX-147 Phase 2 results Q4; VX-548 data Q1 2022.
- CTX001 target enrollment achieved in TDT and SCD trials; regulatory submissions planned late 2022.

## SEC filing metadata
- accession: 0000875320-21-000031
- form_type: 8-K
- ticker: VRTX
- cik: 0000875320
- company_name: VERTEX PHARMACEUTICALS INC / MA
- filed_at: 2021-11-02T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.85
- calibrated_materiality_score: 0.85
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/875320/000087532021000031/0000875320-21-000031-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/875320/000087532021000031/vrtx-20211102.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000875320-21-000031
- JSON: https://secwatch.observer/filing/0000875320-21-000031.json
- Plain text: https://secwatch.observer/filing/0000875320-21-000031.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.